CN Patent

CN118234497A — 通过破坏menin-mll表观遗传复合体靶向治疗胃肠道间质瘤(gist)

Assigned to Dana Farber Cancer Institute Inc · Expires 2024-06-21 · 2y expired

What this patent protects

公开了用于受试者胃肠道间质瘤(GIST)的治疗方法和抑制剂，其具有抑制Menin或Menin‑MLL复合体成员的活性剂。

USPTO Abstract

公开了用于受试者胃肠道间质瘤(GIST)的治疗方法和抑制剂，其具有抑制Menin或Menin‑MLL复合体成员的活性剂。

Drugs covered by this patent

revumenib-citrate (REVUMENIB CITRATE)

Patent Metadata

Patent number: CN118234497A
Jurisdiction: CN
Classification: —
Expires: 2024-06-21
Drug substance claim: No
Drug product claim: No
Assignee: Dana Farber Cancer Institute Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.